drugset / Trial / NCT05673902
Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
Phase 3
Active not recruiting
17 enrolled
R-Pharm International, LLC
Data Management 365 · collabExacte Labs LLC · collabR-Pharm · collabUnimed Laboratories · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of RPH-104 for long-term use in a population of patients with idiopathic recurrent pericarditis who completed the main study CL04018068. The primary objective of the study is to evaluate the safety of RPH-104 80 mg once every 2 weeks in patients with idiopathic recurrent pericarditis who completed the main study.
Timeline
- Start
- 2020-12-11
- Primary completion
- 2026-01
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Goflikicept | Monoclonal antibody | 80 mg | Subcutaneous |